- Home
- VOR vs IKT Comparison
VOR vs IKT Comparison
Compare VOR & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VOR | IKT |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.1M | 201.3M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | VOR | IKT |
|---|---|---|
| Price | $15.70 | $1.68 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 3 |
| Target Price | ★ $64.78 | $6.00 |
| AVG Volume (30 Days) | ★ 1.1M | 647.5K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.62 | $1.33 |
| 52 Week High | $65.80 | $3.32 |
Technical Indicators
Market Signals| Indicator | VOR | IKT |
|---|---|---|
| Relative Strength Index (RSI) | 59.07 | 46.51 |
| Support Level | $13.00 | $1.63 |
| Resistance Level | $14.64 | $1.73 |
| Average True Range (ATR) | 1.45 | 0.14 |
| MACD | 0.30 | -0.04 |
| Stochastic Oscillator | 97.28 | 8.50 |
Price Performance
Historical ComparisonAbout VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.